madman
Super Moderator
Tolmar Collaborates with Direct-to-Patient Telemedicine Company UpScriptHealth to Increase Access to Oral Testosterone Replacement Therapy
/PRNewswire/ -- Tolmar, Inc. ("Tolmar"), a fully integrated pharmaceutical company, announced today the launch of a telemedicine consultation program for...
www.prnewswire.com
BUFFALO GROVE, Ill. and SCOTTSDALE, Ariz., Oct. 23, 2024 /PRNewswire/ -- Tolmar, Inc. ("Tolmar"), a fully integrated pharmaceutical company, announced today the launch of a telemedicine consultation program for JATENZO® (testosterone undecanoate). This program was enabled by Tolmar's engagement of UpScriptHealth, a direct-to-patient telehealth company providing new distribution channels for pharmaceutical and medical device brands. Through their collaboration, UpScriptHealth will provide telehealth consultations for JATENZO, an oral testosterone replacement therapy (TRT) for adult men who have low or no testosterone due to certain medical conditions, including hypogonadism. Men can now visit https://www.jatenzorx.com/products/jatenzo to fill out an online questionnaire and connect directly with a healthcare provider to learn whether JATENZO is right for them.
Launched in 2020, JATENZO was the first branded oral TRT approved in the US by the FDA in more than four decades. Unlike older forms of oral TRT, JATENZO's unique formulation is designed to be safely delivered to the bloodstream without going through the liver first.
Tolmar acquired JATENZO in 2022, advancing the company's focus and commitment to improve access to treatments in Men's Health and Urology. Earlier this year, Tolmar conducted a landmark survey of 303 highly experienced TRT prescribers in the US to examine unmet needs in testosterone replacement therapy. In the survey, physicians reported that 66% of patients stated they switched their TRT within the last year and more than one-quarter do not take their TRT as prescribed.
"The survey results taught us there are many unmet needs for patients in need of TRT and ways that we can better serve these patients. Often times, men do not feel comfortable talking to, or have trouble getting appointments, with their own physician to discuss treatment options for low or no testosterone," said Michele Mazzaccaro, SVP of Commercial Specialty at Tolmar. "Our relationship with UpScriptHealth was established to provide men with low or no testosterone due to certain medical conditions, including hypogonadism, convenient access to physicians' online and more TRT treatment options."
"Our direct-to-patient telemedicine technology ensures that eligible people across the country can access medical care and prescription treatments from the comfort of their home," said Peter Ax, Founder and CEO of UpScriptHealth. "We're proud to partner with Tolmar to provide a more convenient option for patients who seek testosterone replacement therapy."
UpScriptHealth is the company behind the first fully compliant online prescription service in 2002 and has since helped patients access convenient healthcare and more than two million prescriptions. Powered by innovative technology and a telehealth network of hundreds of physicians, UpScriptHealth has forged successful partnerships with dozens of pharma and MedTech businesses to streamline access to treatment while lowering costs.
